isoproterenol has been researched along with pirfenidone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cao, Q; Chen, Z; Huang, X; Lai, H; Ouyang, X; Tao, Y; Wang, S; Wang, Y; Yang, L; Zhou, H | 1 |
2 other study(ies) available for isoproterenol and pirfenidone
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway.
Topics: Animals; Cardiomegaly; Isoproterenol; Mice; Myocytes, Cardiac; Pyridones; Signal Transduction; STAT3 Transcription Factor; TYK2 Kinase; Tyrosine | 2022 |